RBC Capital Reiterates Outperform on Legend Biotech, Maintains $86 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its Outperform rating for Legend Biotech and maintained a price target of $86.

October 29, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Legend Biotech, maintaining a price target of $86, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a price target by RBC Capital suggests continued confidence in Legend Biotech's performance, likely leading to positive sentiment and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100